XML 19 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues:    
Research and development revenue $ 1,601,921 $ 1,681,076
Costs and expenses:    
Costs of research and development revenue 1,424,931 1,459,701
Provision for contract losses 187,388 0
Research and development 3,868,121 3,087,597
Research and development - related party 0 868,720
General and administrative 6,084,799 5,519,922
Foreign currency exchange loss (gain), net 62,345 27,725
Total costs and expenses 11,627,584 10,963,665
Loss from operations (10,025,663) (9,282,589)
Interest income 446,999 984,930
Unrealized gain from investment in Alphazyme 284,709 0
Loss before income taxes (9,293,955) (8,297,659)
Provision for (benefit from) income taxes 31,318 10,306
Net loss $ (9,325,273) $ (8,307,965)
Basic and diluted net loss per common share (in dollars per share) $ (0.34) $ (0.31)
Basic and diluted weighted-average common shares outstanding (in shares) 27,471,587 27,003,695